Skip to main
TRVI

TRVI Stock Forecast & Price Target

TRVI Analyst Ratings

Based on 11 analyst ratings
Strong Buy
Strong Buy 64%
Buy 36%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Trevi Therapeutics Inc. has demonstrated notable progress by successfully completing its End-of-Phase 2 meeting with the U.S. Food and Drug Administration, which reinforces the anticipated timelines for its investigational therapy, Haduvio. The therapy’s unique clinical profile, which includes statistically significant reductions in cough frequency across multiple chronic cough populations, highlights the substantial market opportunity available to the company. Overall, Trevi Therapeutics is viewed as a high-quality investment, with potential for success through both independent operations and strategic partnerships.

Bears say

Trevi Therapeutics Inc faces several significant challenges that contribute to a negative outlook for its stock, primarily related to competitive pressure and reimbursement uncertainty which may hinder its revenue potential. Additionally, the company is exposed to regulatory and trial risks, alongside concerns about capital requirements and operational dependence. These factors combined suggest that despite the potential for Haduvio to generate substantial revenue, the risks involved could severely impact its market performance.

TRVI has been analyzed by 11 analysts, with a consensus rating of Strong Buy. 64% of analysts recommend a Strong Buy, 36% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Trevi Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Trevi Therapeutics Inc (TRVI) Forecast

Analysts have given TRVI a Strong Buy based on their latest research and market trends.

According to 11 analysts, TRVI has a Strong Buy consensus rating as of Mar 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.09, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.09, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Trevi Therapeutics Inc (TRVI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.